FLT3 and acute myeloid leukemia: The unadjusted median OS for patients with FLT3-WT versus FLT3-ITD AML (lengths: <30, 30–53, >53 bp) was 12 months (CI 10.2–15.9) compared to 16.5 months (CI 12.5-NA), 21.8 months (CI 9.8-NA), and 23.6 months (CI 20.2-NA) (p < 0.001).